Multifunctional PSCA Antibody Fragments for PET and Optical Prostate Cancer Imaging
Technical Report,30 Sep 2015,29 Sep 2016
University of California, Los Angeles Los Angeles United States
Pagination or Media Count:
The goals of this initial year of funding were to develop engineered antibody fragments cys-diabodies and cys-minibodies suitable for labeling with positron-emitting radionuclides and fluorescent dyes for multimodal imaging of prostate cancer. A novel cys-minibody recognizing PSCA prostate stem cell antigen has been produced. Conjugation conditions have been developed for radiolabeling with either and I-124 and Zr-89 via lysine random or cysteine site-specific residues of the proteins. Targeting, imaging, and biodistribution studies in mouse models of prostate cancer confirm high activity in PSCA-positive tumors with excellent visualization by PET imaging. Recently, dual-labeling with radionuclide and fluorescent dye of the cys-minibody has been developed and evaluated in mouse models.
- Medicine and Medical Research